Open Societies Need Open Access

The Budapest Open Access Initiative (BOAI) may not have quite the same historic import as the Theses of Martin Luther or the US Declaration of Independence, but it has the potential to shake up the world of academic publishing in a profound way. The BOAI was proposed at a meeting sponsored by the Open Society Institute in Budapest in December 2001, attended by supporters of open access to researcher-generated literature, and was released in final form on Feb. 14 (www.soros.org/openaccess). The O

Written byAlexander Grimwade
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The BOAI states a set of principles and actions designed to free the research literature from the conventional model of publishing research. Scientific research is published by scientists without thought of compensation. Much of the research is supported by public funds. Journals are edited and papers are peer-reviewed by scientists, again mostly without compensation. Finally papers are published in research journals that are made available by subscription. By their nature, subscription prices cause limited access to the literature. Even the best-funded institutions cannot afford every journal, and smaller institutions, less-well-off countries, and most individuals have no access to a significant portion of the literature. It is this restricted access that the BOAI seeks to overcome.

Unlike last year's Public Library of Science declaration, the BOAI does not advocate a boycott of noncomplying publications. However, it does promote a number of steps that authors and journal editors can take to promote ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies